Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions

Neuro-Oncology

Volumn 15, Issue 11, 2013, Pages 1469-1478

  Chmidt, Linnéa ^a   Kling, Teresia ^a   Monsefi, Naser ^a   Olsson, Maja ^a   Hansson, Caroline ^a   Lundgren, Bo ^b   Martens, Ulf ^b   Häggblad, Maria ^b   Westermark, Bengt ^c   Nilsson, Karin Forsberg ^c   Uhrbom, Lene ^c   Karlsson Lindahl, Linda ^a   Gerlee, Philip ^d   Nelander, Sven ^a  

^a Department of Obstetrics and Gynecology   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Drug combination responses; Glioblastoma stem cell cultures; Glioblastoma therapy; Predictive medicine

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; CEFACLOR; DOXORUBICIN; ERLOTINIB; FLUPERLAPINE; GEFITINIB; IMATINIB; IMIPRAMINE; IPRIFLAVONE; METFORMIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; NELARABINE; OLOMOUCINE; PACLITAXEL; PHYSOSTIGMINE; PIRENPERONE; PIROXICAM; QUERCETIN; RAPAMYCIN; RETINOIC ACID; RIMCAZOLE; ROSCOVITINE; SERTRALINE; TEMOZOLOMIDE; UNINDEXED DRUG; WORTMANNIN; ZOLMITRIPTAN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG PAIR SCREENING; DRUG SCREENING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE;

DRUG COMBINATION RESPONSES; GLIOBLASTOMA STEM CELL CULTURES; GLIOBLASTOMA THERAPY; PREDICTIVE MEDICINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAZOLES; CELL LINE, TUMOR; DRUG INTERACTIONS; GLIOBLASTOMA; HUMANS; QUINAZOLINES; SERTRALINE; STILBENES;

EID: 84891866810     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not111     Document Type: Article

References (40)

1. Louis DN, Holland EC, Cairncross JG. Glioma classification: amolecular reappraisal. Am J Pathol. 2001;159(3):779-786
2. AdamsonC,KanuOO,MehtaAI, et al. Glioblastomamultiforme: A review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18(8):1061-1083
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996
4. Marosi C. Chemotherapy for malignant gliomas. WienMedWochenschr. 2006;156(11-12):346-350
5. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003
6. Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5(1):102-114
7. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12(1-2):34-42
8. Lehar J, Krueger AS, AveryW, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009; 27(7):659-666
9. DeVita VT, Jr., Hellman S, Rosenberg SA. Principles of Cancer Management: Chemotherapy. Philadelphia: Lippincott; 1997:333-347
10. University of California San Francisco, Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma (AVF4120s). In: ClinicalTrials.gov [Internet], National Library of Medicin (US), 2012-05-04. Michael D. Prados. (MD)(NCT00525525)
11. Oncology, M.U.M.C.M.R., Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma. In: ClinicalTrials.gov [Internet], National Library of Medicin (US), 2012-05-04. Brigitta Baumert (MD)(NCT00694837)
12. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;4(1):71-78
13. Yeh P, Tschumi AI, Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat Genet. 2006;38(4):489-494
14. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul.1984;22:27-55
15. Zhao L, Au JL, Wientjes MG. Comparison of methods for evaluating drugdrug interaction. Front Biosci (Elite Ed). 2010;2:241-249
16. Greco WR,Bravo G,Parsons JC. Thesearchfor synergy:acritical reviewfrom a response surface perspective. Pharmacol Rev. 1995;47(2):331-385
17. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the sigma-1receptor cause selective release of the deathprogramin tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64(14):4875-4886
18. Gil-Ad I, Zolokov A, Lomnitski L, et al. Evaluation of the potential anticancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol. 2008;33(2):277-286
19. Pollard SM, Yoshikawa K, Clarke ID, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009;4(6):568-580
20. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9(3):469-479
21. Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol. 1939;26:585-615
22. Loewe SMH. Effects of combinations: mathematical basis of problem. Arch Exp Pathol Pharmakol. 1926;114:313-326
23. Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41(2):93-141
24. Berenbaum MC. The expected effect of a combination of agents: the general solution. J Theor Biol. 1985;114(3):413-431
25. Cokol M, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol. 2011;7:544
26. Witten DM, Tibshirani RJ. Extensions of sparse canonical correlation analysis with applications to genomic data. Stat Appl Genet Mol Biol. 2009;8(1):1-27. Article28
27. Segre D, Deluna A, Church GM, et al. Modular epistasis in yeast metabolism. Nat Genet. 2005;37(1):77-83
28. Lehár J, ZimmermannGR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007;3:80
29. Lin CJ, Robert F, Sukarieh R, et al. The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling. Cancer Res. 2010;70(8):3199-3208
30. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391-403
31. Lipscomb EA, Mercurio AM. Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev. 2005;24(3):413-423
32. Wang K, Diskin SJ, Zhang H, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011;469(7329):216-220
33. Ferletta M,Caglayan D, Mokvist L, et al. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells. Int J Cancer. 2011;129(1):45-60
34. Huang J, Zhang Y-L, Teng X-M, et al. Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer. 2007;7:126
35. Zhu HJ, Patrick KS, Yuan HJ, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82(6):1241-1248
36. Wang Y, Ding L,Wang X, et al. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am J Transl Res. 2012;4(1):44-51
37. Opel D,Westhoff MA, Bender A, et al. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor-and drug-induced apoptosis. Cancer Res. 2008;68(15):6271-6280
38. Wang YA, Johnson SK, Brown BL, et al. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int J Cancer. 2008;123(7):1536-1544
39. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173
40. Verhaak RG,Hoadley KA,Purdom E, et al. Integratedgenomicanalysis identifiescl inically relevant subtypes of glioblastoma characterized byabnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110